Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on UK Post Observer.
Press releases published on April 12, 2025
Riyadh to Host EDGEx 2025: Beyond Readiness - Where Education Meets Innovation
EIN Presswire
·
April 12, 2025
RIYADH, SAUDI ARABIA, April 12, 2025 /EINPresswire.com/ -- The Kingdom of Saudi Arabia is set to transform the educational landscape as the Saudi Ministry of Education prepares to launch the groundbreaking International Education Exhibition (EDGEx). …
Soul-Stirring New Single 'Love U this Late' Arrives Right on Time
EIN Presswire
·
April 12, 2025
Anjalts shares the sixth song lifted from her upcoming third album LOS ANGELES, CA, UNITED STATES, April 12, 2025 /EINPresswire.com/ -- There is a grounded ever-glow of creativity that radiates from this multi-instrumentalist/producer. Her music simmers …
Weaving Happiness: World Happiness Foundation and Jaipur Rugs Unite for Artisan Well-Being and Global Harmony
EIN Presswire
·
April 12, 2025
The goal is to create a regenerative loop where artisans, their families, and communities experience well-being from the inside out. MIAMI, FL, UNITED STATES, April 12, 2025 /EINPresswire.com/ -- In a powerful alliance rooted in purpose, the World …
EricMalley.com Releases Article on Navigating Tariff-Driven Economic Shifts
EIN Presswire
·
April 12, 2025
As global markets grapple with $4 trillion in losses, Eric Malley offers a timely analysis of how stablecoins can emerge as a practical solution. NEW YORK, NY, UNITED STATES, April 12, 2025 /EINPresswire.com/ -- EricMalley.com announces the release of " …
Vantage Biosciences 完成口服 VX-01 治疗非增殖性糖尿病视网膜病变第 2 期临床研究首例患者的给药
GlobeNewswire
·
April 12, 2025
伦敦, April 12, 2025 (GLOBE NEWSWIRE) -- Vantage Biosciences，一家推进糖尿病眼疾创新治疗的临床阶段生物技术公司，于今日宣布已在评估 VX-01 的第 2 期临床研究中成功完成首例患者的给药，VX-01 是治疗非增殖性糖尿病视网膜病变 (NPDR) 的一种口服疗法。 糖尿病视网膜病变影响全球超 1 亿人，也是劳动年龄段成人失明的主要诱因之一。 若未及时干预，NPDR 可能发展到糖尿病眼疾的更严重阶段，从而增加视力丧失的风险。 该里程碑标志着 VX-01 …
Vantage Biosciences 的口服藥 VX-01 用於治療非增生性糖尿病視網膜病變，在其第 2 期臨床研究中，首次安排患者完成服藥
GlobeNewswire
·
April 12, 2025
倫敦, April 12, 2025 (GLOBE NEWSWIRE) -- Vantage Biosciences 是一間臨床階段生物科技公司，致力開發治療糖尿病眼疾的創新療法。該公司今天宣布，在其評估 VX-01 的第 2 期臨床研究中，首次安排患者成功服藥。VX-01 是一種用於治療非增生性糖尿病視網膜病變 (NPDR) 的口服藥。 糖尿病視網膜病變影響全球逾 1 億人，是就業年齡成人失明的主要原因之一。 如果不及時介入，NPDR 可能會導致糖尿病眼疾的情況變得更加嚴重，增加視力受損的風險。 …
Infini Revives Infini Earn with New Security Architecture and Global Access
GlobeNewswire
·
April 12, 2025
HONG KONG, April 12, 2025 (GLOBE NEWSWIRE) -- Infini, the innovative crypto payment and earning platform, is excited to announce the return of its highly anticipated feature, Infini Earn. Designed to seamlessly merge crypto payments with asset growth, …